Literature DB >> 6395953

New agents in non-small cell lung cancer.

R A Joss, F Cavalli, A Goldhirsch, B Mermillod, K W Brunner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6395953     DOI： 10.1016/0305-7372(84)90009-4

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN： 0305-7372            Impact factor:   12.111


× No keyword cloud information.
  9 in total

1.  Etoposide in patients with previously untreated non-small-cell lung cancer: a phase I study.

Authors:  N Niederle; J Ostermann; W Achterrath; L Lenaz; C G Schmidt
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

2.  Phase II study of (glycolate-O,O') diammineplatinum(II), a novel platinum complex, in the treatment of non-small-cell lung cancer.

Authors:  M Fukuda; T Shinkai; K Eguchi; Y Sasaki; T Tamura; Y Ohe; A Kojima; F Oshita; K Hara; N Saijo
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Cisplatin, ifosfamide and vindesine in the chemotherapy of non-small-cell lung cancer: a combination phase II study.

Authors:  R Honda; A Fujita; Y Inoue; M Asakawa; A Suzuki
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

4.  Phase II study of carboplatin in untreated, inoperable non-small-cell lung cancer.

Authors:  U Gatzemeier; M Heckmayr; D K Hossfeld; R Zschaber; W Achterrath; L Lenaz
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 5.  Vinorelbine. A review of its antitumour activity in lung cancer.

Authors:  J B Sørensen
Journal:  Drugs       Date:  1992       Impact factor: 9.546

6.  Phase II study of Edatrexate in stage III and IV non-small-cell lung cancer.

Authors:  R L Souhami; R M Rudd; S G Spiro; R Allen; P Lamond; P G Harper
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 7.  Single-agent chemotherapy for advanced adenocarcinoma of the lung. A review.

Authors:  J B Sørensen; M Clerici; H H Hansen
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

8.  Single agent activity of rhizoxin in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group.

Authors:  S Kaplan; A R Hanauske; N Pavlidis; U Bruntsch; A te Velde; J Wanders; B Heinrich; J Verweij
Journal:  Br J Cancer       Date:  1996-02       Impact factor: 7.640

9.  Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG)

Authors:  T Cerny; S Kaplan; N Pavlidis; P Schöffski; R Epelbaum; J van Meerbeek; J Wanders; H R Franklin; S Kaye
Journal:  Br J Cancer       Date:  1994-08       Impact factor: 7.640
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.